리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 381 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 상실성빈박 시장은 2030년까지 10억 달러에 달할 전망
2024년에 6억 4,880만 달러로 추정되는 세계의 상실성빈박 시장은 2030년에는 10억 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 8.3%로 성장할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 Atrioventricular Nodal Re-entrant Tachycardia는 CAGR 10.8%를 기록하며, 분석 기간 종료시에는 4억 8,420만 달러에 달할 것으로 예측됩니다. Atrioventricular Reciprocating Tachycardia 부문의 성장률은 분석 기간에 CAGR 6.2%로 추정됩니다.
미국 시장은 1억 7,680만 달러, 중국은 CAGR 13.4%로 성장 예측
미국의 상실성빈박시장은 2024년에 1억 7,680만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR을 13.4%로, 2030년까지 2억 3,140만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.0%와 8.1%로 예측됩니다. 유럽에서는 독일이 CAGR 5.5%로 성장할 것으로 예측됩니다.
세계의 상실성빈박 시장 동향과 촉진요인 정리
상심실성 빈맥이란 무엇이며, 왜 중요한가?
상심실성 빈맥(SVT)은 심장의 심실 상부에서 발생하는 부정맥의 일종으로 비정상적으로 빠른 심장 박동 리듬을 일으켜 심장 기능을 현저하게 방해하는 부정맥을 말합니다. 일반적으로 생명을 위협하지는 않지만, SVT는 환자를 고통스럽고 쇠약하게 만들 수 있으며, 종종 심계항진, 현기증, 흉통, 피로 등의 증상을 유발합니다. SVT에는 심방 결절 재진입성 빈맥(AVNRT), 심방 왕복성 빈맥(AVRT), 심방 빈맥 등의 하위 유형이 있습니다. 이러한 부정맥은 종종 전기적 재진입 회로 또는 심장 조직의 비정상적인 자동성에 의해 유발됩니다.
SVT의 임상적 중요성은 높은 재발률, 예측 불가능한 발병, 특히 고령자 및 합병증을 가진 집단에서 삶의 질을 저해할 수 있다는 점입니다. SVT의 유병률은 전 세계에서 증가하고 있으며, 인구 고령화, 심혈관 검진 증가, 고혈압 및 구조적 심장질환의 유병률 증가가 그 원인으로 꼽힙니다. 급성 에피소드는 종종 미주신경 조작이나 아데노신과 같은 약물로 종식시킬 수 있지만, 많은 환자들은 장기적인 관리 전략이 필요합니다. 이를 위해 전기생리학, 장치를 이용한 중재, 약물 치료 등의 기술 혁신이 절실히 요구되고 있습니다.
진단 및 치료 프로토콜은 기술과 함께 어떻게 진화하고 있는가?
SVT의 진단과 치료는 정교한 진단 툴와 중재 기술의 통합으로 크게 발전했습니다. 홀터 모니터, 이식형 루프 리코더, 휴대용 심전도 장치 등으로 진료 중 발견되지 않을 수 있는 일시적인 SVT 에피소드를 정확하게 포착할 수 있게 되었습니다. 비침습적 매핑 기술을 통해 전기생리학자들은 부정맥 발생 병소의 위치를 놀라울 정도로 정확하게 파악할 수 있게 되어 보다 정밀한 치료의 토대를 마련하고 있습니다.
특히 카테터 절제술은 최소 침습적이고 종종 근본적인 해결책을 제공함으로써 SVT 관리에 혁명을 일으켰습니다. 3D 전기해부학 매핑, 심초음파, 원격 자기 네비게이션과 같은 기술 혁신으로 최신 절제 시스템은 현재 더 높은 효과, 더 낮은 재발률, 더 높은 안전성을 실현하고 있습니다. 약리학적 측면에서는 부정맥 위험을 감소시킨 새로운 항부정맥제가 임상적으로 적용되고 있습니다. 유전적 소인, 해부학적 변이, 동반 질환을 고려한 개인별 맞춤 치료 접근법도 보급되고 있으며, SVT 치료에 있으며, 보다 개인화된 표준 치료의 길이 열리고 있습니다.
SVT 치료제의 세계 정세에 영향을 미치는 시장 동향은?
의료의 디지털화, 심혈관계에 대한 인식 증가, 첨단 심장 치료에 대한 접근성 확대가 SVT 시장 전망을 재구성하고 있습니다. 웨어러블 심전도 모니터와 모바일 헬스 앱의 보급은 특히 외래 환자나 지방의 조기 진단에 힘을 실어주고 있습니다. 이 장치들은 실시간 리듬 추적과 심장 전문의와의 데이터 공유를 통해 적시에 개입할 수 있도록 도와줍니다. 클라우드 플랫폼 및 AI 알고리즘과의 통합을 통해 부정맥 감지 정확도를 향상시키고, 환자별 데이터 패턴에 기반한 실용적인 인사이트를 임상의에게 제공합니다.
진단과 병행하여, 장비 제조업체들은 개선된 에너지 공급 시스템, 실시간 피드백 메커니즘, AI 지원 시술 가이드를 갖춘 차세대 절제용 카테터 개발을 진행하고 있습니다. 또한 시술의 편차와 방사선 피폭을 줄이기 위해 로봇 네비게이션 시스템도 검토되고 있습니다. 의약품 측면에서는 장기적으로 사용할 수 있는 심박수 및 리듬 조절 약물 개발에 다시 한 번 초점을 맞추었습니다. 규제 당국은 새로운 항부정맥제 및 절제 장치의 승인 경로를 간소화하여 신속한 임상 도입을 촉진하고 있습니다. 심장 인프라가 미비한 지역에서는 민관 협력과 이동식 전기생리학적 치료 장비가 치료 격차를 해소하고 치료 접근성을 개선하는 데 도움이 되고 있습니다.
상심실성 빈맥 시장 수요 증가 요인은 무엇인가?
상심실성 빈맥 시장의 성장은 임상적 요구, 기술 혁신, 의료 인프라 확장과 관련된 여러 요인에 의해 주도되고 있습니다. 심혈관 질환의 유병률 증가, 특히 고령화 인구 증가로 인해 심방세동 진단이 급증하고 있으며, 보다 효과적인 장기적 치료 옵션이 필요합니다. 고혈압, 당뇨병, 비만 증가는 부정맥 감수성 증가에 기여하고 있으며, 치료 인구를 더욱 확대시키고 있습니다.
또한 전기생리학적 기술, 특히 고주파 및 냉동 절제 시스템의 급속한 발전으로 인터벤션 치료가 더욱 친숙하고 성공적일 수 있게 되었습니다. 웨어러블 심장 모니터링 기기의 도입은 조기 진단을 촉진하고, 시술 의뢰를 증가시키고 있습니다. 선진국과 신흥 경제국 모두에서 심장 전문센터의 개발과 숙련된 전기생리학자의 확보가 절제술 서비스의 확장을 지원하고 있습니다. 이와 함께 보다 안전한 항부정맥제에 초점을 맞춘 의약품의 연구개발과 심박수 조절을 위한 복합제의 가용성이 약물 치료 분야에 활력을 불어넣고 있습니다.
디지털 의료 인프라에 대한 투자와 함께 심혈관계 질환의 이환율을 낮추기 위한 정부의 구상도 중요한 역할을 하고 있습니다. 상환 정책의 개선과 절제술이 국가 보험제도에 임베디드되면서 더 많은 환자들이 결정적인 치료를 받을 수 있게 되었습니다. 마지막으로 부정맥과 최신 심장 치료법의 안전성에 대한 대중의 인식이 높아짐에 따라 편견이 줄어들고 적극적인 건강관리 행동이 촉진되고 있습니다.
부문
유형(Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, 심방세동, 기타 유형), 치료(약물 요법, 고주파 카테터 절제, 수술), 최종사용자(병원·진료소 최종사용자, 외래 수술 센터 최종사용자, 진단 센터 최종사용자, 기타 최종사용자)
조사 대상 기업의 예
Abbott Laboratories
Amomed Pharma GmbH
AstraZeneca plc
Bayer AG
Biotronik SE & Co. KG
Boston Scientific Corporation
Bristol-Myers Squibb Company
Covis Pharma BV
GlaxoSmithKline plc
Glenmark Pharmaceuticals
Johnson & Johnson Private Limited
Mayne Pharma Group Limited
Medtronic plc
Merck Sharp & Dohme Corp.(MSD)
Milestone Pharmaceuticals
Novartis AG
Pfizer Inc.
Sanofi S.A.
St. Jude Medical(Abbott)
Teva Pharmaceutical Industries Ltd
Upsher-Smith Laboratories, LLC
AI 통합
Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 큐레이트된 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Supraventricular Tachycardia Market to Reach US$1.0 Billion by 2030
The global market for Supraventricular Tachycardia estimated at US$648.8 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Atrioventricular Nodal Re-entrant Tachycardia, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$484.2 Million by the end of the analysis period. Growth in the Atrioventricular Reciprocating Tachycardia segment is estimated at 6.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$176.8 Million While China is Forecast to Grow at 13.4% CAGR
The Supraventricular Tachycardia market in the U.S. is estimated at US$176.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$231.4 Million by the year 2030 trailing a CAGR of 13.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.
Global Supraventricular Tachycardia Market - Key Trends & Drivers Summarized
What Exactly Is Supraventricular Tachycardia and Why Does It Matter?
upraventricular Tachycardia (SVT) refers to a group of arrhythmias that originate above the ventricles in the heart, causing abnormally fast heart rhythms that can significantly disrupt cardiac function. Though not typically life-threatening, SVT can be distressing and debilitating for patients, often causing symptoms such as palpitations, dizziness, chest pain, and fatigue. The condition includes several subtypes such as atrioventricular nodal reentrant tachycardia (AVNRT), atrioventricular reciprocating tachycardia (AVRT), and atrial tachycardia. These arrhythmias are often triggered by electrical re-entry circuits or abnormal automaticity in cardiac tissue.
The clinical significance of SVT lies in its high recurrence rate, unpredictable onset, and the potential to impair quality of life, especially in elderly and comorbid populations. The prevalence of SVT is increasing globally, partly due to aging populations, increased cardiovascular screening, and higher rates of hypertension and structural heart disease. While acute episodes can often be terminated with vagal maneuvers or medications like adenosine, many patients require long-term management strategies. This has created a strong demand for innovations in electrophysiology, device-based interventions, and pharmacological therapy.
How Are Diagnosis and Treatment Protocols Evolving with Technology?
he diagnosis and treatment of SVT have advanced considerably with the integration of sophisticated diagnostic tools and interventional techniques. Holter monitors, implantable loop recorders, and mobile ECG devices have enabled the accurate capture of transient SVT episodes that might otherwise go undetected during clinic visits. Non-invasive mapping technologies are helping electrophysiologists localize arrhythmogenic foci with remarkable precision, laying the foundation for more targeted treatments.
Catheter ablation, in particular, has revolutionized SVT management by offering a minimally invasive, often curative solution. Powered by innovations in 3D electroanatomical mapping, intracardiac echocardiography, and remote magnetic navigation, modern ablation systems now offer improved efficacy, lower recurrence rates, and enhanced safety profiles. On the pharmacological front, newer antiarrhythmic agents with reduced proarrhythmic risk are entering clinical use. Personalized therapy approaches that factor in genetic predisposition, anatomical variations, and comorbid conditions are also gaining traction, paving the way for a more individualized standard of care in SVT treatment.
What Market Trends Are Influencing the Global SVT Therapeutics Landscape?
ealthcare digitization, rising cardiovascular awareness, and growing access to advanced cardiac care are reshaping the SVT market landscape. The proliferation of wearable ECG monitors and mobile health apps is empowering early diagnosis, particularly in outpatient and rural settings. These devices allow real-time rhythm tracking and data sharing with cardiologists, enabling timely interventions. Integration with cloud platforms and AI algorithms is also improving arrhythmia detection accuracy and providing clinicians with actionable insights based on patient-specific data patterns.
Parallel to diagnostics, device manufacturers are developing next-generation ablation catheters with improved energy delivery systems, real-time feedback mechanisms, and AI-assisted procedural guidance. Robotic navigation systems are also being explored to reduce procedural variability and radiation exposure. On the pharmaceutical front, there's renewed focus on developing rate- and rhythm-control medications with better tolerability for long-term use. Regulatory bodies are streamlining approval pathways for novel antiarrhythmic drugs and ablation devices, encouraging rapid clinical adoption. In regions with underdeveloped cardiac infrastructure, public-private partnerships and mobile electrophysiology units are helping close treatment gaps and increase procedural accessibility.
What’s Fueling the Rising Demand in the Supraventricular Tachycardia Market?
he growth in the supraventricular tachycardia market is driven by several factors linked to clinical need, technological innovation, and healthcare infrastructure expansion. The increasing prevalence of cardiovascular diseases-particularly among aging populations-is leading to a surge in SVT diagnoses, necessitating more effective long-term treatment options. Rising rates of hypertension, diabetes, and obesity are contributing to higher arrhythmia susceptibility, further expanding the treatment population.
Moreover, the rapid advancement of electrophysiology technologies-especially radiofrequency and cryoablation systems-is making interventional treatment more accessible and successful. The adoption of wearable cardiac monitoring devices is driving early diagnosis and increasing procedural referrals. Growth in cardiac specialty centers and the availability of trained electrophysiologists in both developed and emerging economies are supporting the expansion of ablation services. In parallel, pharmaceutical R&D focused on safer antiarrhythmic drugs and the availability of fixed-dose combinations for rate control are boosting pharmacotherapy segments.
Government initiatives aimed at reducing cardiovascular morbidity, alongside investments in digital health infrastructure, are also playing a critical role. Reimbursement policy improvements and inclusion of ablation in national insurance programs are encouraging more patients to pursue definitive treatments. Lastly, increasing public awareness about arrhythmias and the safety of modern cardiac procedures is reducing stigma and driving proactive healthcare behavior-all of which are fueling robust growth across the SVT diagnostics and therapeutics market.
SCOPE OF STUDY:
The report analyzes the Supraventricular Tachycardia market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation, Other Types); Treatment (Medications, Radiofrequency Catheter Ablation, Surgery); End-Use (Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use, Diagnostic Centers End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 42 Featured) -
Abbott Laboratories
Amomed Pharma GmbH
AstraZeneca plc
Bayer AG
Biotronik SE & Co. KG
Boston Scientific Corporation
Bristol-Myers Squibb Company
Covis Pharma BV
GlaxoSmithKline plc
Glenmark Pharmaceuticals
Johnson & Johnson Private Limited
Mayne Pharma Group Limited
Medtronic plc
Merck Sharp & Dohme Corp. (MSD)
Milestone Pharmaceuticals
Novartis AG
Pfizer Inc.
Sanofi S.A.
St. Jude Medical (Abbott)
Teva Pharmaceutical Industries Ltd
Upsher-Smith Laboratories, LLC
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Supraventricular Tachycardia - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Cardiac Rhythm Disorders Throws the Spotlight on Diagnosis and Management of SVT
Advances in Electrophysiology and Mapping Technologies Propel Innovation in SVT Ablation Therapies
Growing Use of Wearable ECG Monitors Enhances Early Detection and Patient-Reported SVT Episodes
Increase in Minimally Invasive Cardiac Procedures Strengthens Business Case for Catheter Ablation Devices
Development of Next-Gen Antiarrhythmic Drugs Expands Pharmacological Management Options
Expansion of Ambulatory Heart Monitoring Services Accelerates Market for Holter and Patch Monitors
AI-Based Arrhythmia Detection Algorithms Improve SVT Diagnosis and Personalized Treatment
Rising Healthcare Infrastructure in Emerging Economies Supports Broader Access to EP Labs and Treatments
FDA Approvals and Clinical Guidelines Drive Adoption of SVT Ablation in First-Line Treatment Protocols
Patient Awareness Campaigns and Cardiology Screening Programs Spur Earlier Diagnosis and Intervention
Integration of SVT Management in Telecardiology Platforms Expands Reach and Efficiency of Care
Collaborative Research in Pediatric SVT Opens New Frontiers in Age-Specific Treatment Strategies
Growing Cardiologist Workforce and Specialization Boost Market Capacity for EP and SVT Procedures
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Supraventricular Tachycardia Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Supraventricular Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Supraventricular Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Atrioventricular Nodal Re-entrant Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Atrioventricular Nodal Re-entrant Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Atrioventricular Nodal Re-entrant Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Atrioventricular Reciprocating Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Atrioventricular Reciprocating Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Atrioventricular Reciprocating Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Atrial Fibrillation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Hospital & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 28: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 31: World 16-Year Perspective for Medications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Radiofrequency Catheter Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Radiofrequency Catheter Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 34: World 16-Year Perspective for Radiofrequency Catheter Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 37: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 40: USA 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 43: USA 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 46: USA 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 49: Canada 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 52: Canada 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 55: Canada 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
JAPAN
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 56: Japan Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 58: Japan 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 61: Japan 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 64: Japan 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
CHINA
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 65: China Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 67: China 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: China Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 70: China 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: China Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 73: China 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
EUROPE
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 74: Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Supraventricular Tachycardia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 76: Europe 16-Year Perspective for Supraventricular Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 79: Europe 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 82: Europe 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 85: Europe 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
FRANCE
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 86: France Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 88: France 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: France Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 91: France 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: France Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 94: France 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
GERMANY
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 95: Germany Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 97: Germany 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 100: Germany 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 103: Germany 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 106: Italy 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 109: Italy 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 112: Italy 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
UNITED KINGDOM
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 113: UK Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 115: UK 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: UK Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 118: UK 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: UK Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 121: UK 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
SPAIN
TABLE 122: Spain Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 124: Spain 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 125: Spain Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Spain Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 127: Spain 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 128: Spain Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Spain Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 130: Spain 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
RUSSIA
TABLE 131: Russia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 133: Russia 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 134: Russia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Russia Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 136: Russia 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 137: Russia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Russia Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 139: Russia 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 142: Rest of Europe 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 145: Rest of Europe 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 148: Rest of Europe 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Supraventricular Tachycardia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 151: Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 154: Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 157: Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 160: Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
AUSTRALIA
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 161: Australia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 163: Australia 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 164: Australia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Australia Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 166: Australia 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 167: Australia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Australia Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 169: Australia 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
INDIA
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 170: India Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: India Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 172: India 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 173: India Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: India Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 175: India 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 176: India Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: India Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 178: India 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 179: South Korea Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 181: South Korea 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 182: South Korea Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 184: South Korea 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 185: South Korea Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: South Korea Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 187: South Korea 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
LATIN AMERICA
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 197: Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Supraventricular Tachycardia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 199: Latin America 16-Year Perspective for Supraventricular Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 202: Latin America 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 205: Latin America 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 206: Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 208: Latin America 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 209: Argentina Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 211: Argentina 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 212: Argentina Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 214: Argentina 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 215: Argentina Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 216: Argentina Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 217: Argentina 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
BRAZIL
TABLE 218: Brazil Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 220: Brazil 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 221: Brazil Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 223: Brazil 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 224: Brazil Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 225: Brazil Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 226: Brazil 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
MEXICO
TABLE 227: Mexico Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 229: Mexico 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 230: Mexico Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 232: Mexico 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 233: Mexico Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 234: Mexico Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 235: Mexico 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 238: Rest of Latin America 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 241: Rest of Latin America 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Latin America Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 244: Rest of Latin America 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
MIDDLE EAST
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 245: Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Supraventricular Tachycardia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 247: Middle East 16-Year Perspective for Supraventricular Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 250: Middle East 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 253: Middle East 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 254: Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 256: Middle East 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
IRAN
TABLE 257: Iran Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 259: Iran 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 260: Iran Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 261: Iran Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 262: Iran 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 263: Iran Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 264: Iran Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 265: Iran 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
ISRAEL
TABLE 266: Israel Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 268: Israel 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 269: Israel Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 270: Israel Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 271: Israel 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 272: Israel Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 273: Israel Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 274: Israel 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 277: Saudi Arabia 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 280: Saudi Arabia 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 282: Saudi Arabia Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 283: Saudi Arabia 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 284: UAE Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 286: UAE 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 287: UAE Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 288: UAE Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 289: UAE 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 290: UAE Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 291: UAE Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 292: UAE 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 295: Rest of Middle East 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 298: Rest of Middle East 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 300: Rest of Middle East Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 301: Rest of Middle East 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
AFRICA
Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 302: Africa Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 304: Africa 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
TABLE 305: Africa Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 306: Africa Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 307: Africa 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
TABLE 308: Africa Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 309: Africa Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 310: Africa 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030